Trials / Completed
CompletedNCT00141791
Study Evaluating Etanercept in Moderate to Severe Asthma
A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Safety and Efficacy of Etanercept 25mg Twice Weekly in Subjects With Moderate to Severe Persistent Asthma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to assess the efficacy and safety of etanercept 25 mg given twice weekly in subjects with moderate to severe persistent asthma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Etanercept |
Timeline
- Start date
- 2005-05-01
- Primary completion
- 2006-07-01
- Completion
- 2006-07-01
- First posted
- 2005-09-01
- Last updated
- 2009-08-07
Locations
13 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00141791. Inclusion in this directory is not an endorsement.